for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Glenmark Pharmaceuticals Ltd

GLEN.NS

Latest Trade

426.65INR

Change

-5.30(-1.23%)

Volume

3,395,204

Today's Range

424.95

 - 

439.35

52 Week Range

161.65

 - 

573.05

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
431.95
Open
432.25
Volume
3,395,204
3M AVG Volume
192.90
Today's High
439.35
Today's Low
424.95
52 Week High
573.05
52 Week Low
161.65
Shares Out (MIL)
282.17
Market Cap (MIL)
120,387.00
Forward P/E
15.30
Dividend (Yield %)
0.47

Next Event

Q1 2021 Glenmark Pharmaceuticals Ltd Earnings Release

Latest Developments

More

Glenmark Pharmaceuticals Gets Indian Regulator Nod For Favipiravir

Glenmark Gets Regulator Nod For Clinical Trials In India On Favipiravir Antiviral Tablets For COVID-19 Patients

Glenmark Pharma Gets ANDA Tentative Approval For Dapagliflozin & Saxagliptin Tablets

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.

Industry

Biotechnology & Drugs

Contact Info

B D S Marg

Chakala, Off Western Express Highway

Andheri (E),

400099

India

+91.22.40189999

http://glenmarkpharma.com/

Executive Leadership

Glenn Mario Saldanha

Executive Chairman of the Board, Chief Executive Officer, Managing Director

V. S. Mani

Global Chief Financial Officer, Executive Director

Harish Kuber

Compliance Officer, Company Secretary

Cherylann Pinto

Director - Corporate Affairs, Executive Director

Rajesh V. Desai

Non-Executive Director

Key Stats

2.65 mean rating - 26 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2018

91.0K

2019

98.7K

2020

106.4K

2021(E)

114.3K
EPS (INR)

2018

28.490

2019

26.860

2020

26.330

2021(E)

27.890
Price To Earnings (TTM)
15.51
Price To Sales (TTM)
1.13
Price To Book (MRQ)
1.98
Price To Cash Flow (TTM)
10.09
Total Debt To Equity (MRQ)
73.89
LT Debt To Equity (MRQ)
66.60
Return on Investment (TTM)
7.82
Return on Equity (TTM)
5.55

Latest News

Latest News

U.S. charges generic drug firm Glenmark with price-fixing

Glenmark Pharmaceuticals USA was charged on Tuesday with conspiring to fix prices for generic drugs, the U.S. Justice Department said in a statement.

BRIEF-Hindustan Unilever Ltd Says Completes Acquisition Of Vwash From Glenmark Pharmaceuticals

* HINDUSTAN UNILEVER LTD - HINDUSTAN UNILEVER COMPLETES ACQUISITION OF VWASH FROM GLENMARK PHARMACEUTICALS Source text for Eikon: Further company coverage:

Glenmark gets India approval for favipiravir as COVID-19 treatment

Glenmark Pharmaceuticals Ltd has received Indian regulatory approval to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 infections in the country, it said on Friday.

Glenmark gets India approval for favipiravir as COVID-19 treatment

Glenmark Pharmaceuticals Ltd said on Friday it had received an approval from India's drugs regulator to make and sell oral antiviral drug favipiravir for treating mild-to-moderate COVID-19 patients in the country.

BRIEF-Glenmark Pharmaceuticals Gets Indian Regulator Nod For Favipiravir

* INDIAN REGULATOR APPROVES FAVIPIRAVIR FOR TREATMENT OF MILD TO MODERATE COVID-19 IN INDIA

India's Glenmark to study potential COVID-19 drug combination

Glenmark Pharmaceuticals Ltd <GLEN.NS> said on Tuesday it would begin a clinical trial in India to test a combination of two anti-viral drugs, favipiravir and umifenovir, as a potential COVID-19 treatment.

India's Glenmark to study potential COVID-19 drug combination

Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial in India to test a combination of two anti-viral drugs - favipiravir and umifenovir - as a potential COVID-19 treatment.

BRIEF-Glenmark Pharmaceuticals Launches 3-In-1 Inhaler Therapy For COPD In India

* GLENMARK INTRODUCES 3-IN-1 INHALER THERAPY FOR COPD IN INDIA Source text for Eikon: Further company coverage:

Glenmark to conduct trials in India for potential COVID-19 drug

Glenmark Pharmaceuticals Ltd <GLEN.NS> said on Thursday it will start clinical trials in India of antiviral drug favipiravir, seen as a potential treatment for COVID-19, sending its shares up as much as 9%.

India's Glenmark to conduct trials for potential COVID-19 drug, shares jump

Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

BRIEF-Glenmark Gets Regulator Nod For Clinical Trials In India On Favipiravir Antiviral Tablets For COVID-19 Patients

* RECEIVES APPROVAL FROM REGULATOR (DCGI) TO CONDUCT CLINICAL TRIALS IN INDIA ON FAVIPIRAVIR ANTIVIRAL TABLETS FOR COVID-19 PATIENTS Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharma Gets ANDA Tentative Approval For Dapagliflozin & Saxagliptin Tablets

* GETS ANDA TENTATIVE APPROVAL FOR DAPAGLIFLOZIN & SAXAGLIPTIN TABLETS, 10 MG/5 MG Source text for Eikon: Further company coverage:

BRIEF-Glenmark Pharmaceuticals-Gets ANDA Tentative Approval For Dapagliflozin Tablets 5, 10 MG

* GLENMARK PHARMACEUTICALS LTD -RECEIVES ANDA TENTATIVE APPROVAL FOR DAPAGLIFLOZIN TABLETS, 5 MG AND 10 MG Source text for Eikon: Further company coverage:

BRIEF-India's Glenmark Pharma & UK's Hikma Enter Exclusive Licensing Agreement For Nasal Spray In U.S.

* SAYS CO, HIKMA ENTER EXCLUSIVE LICENSING AGREEMENT FOR COMMERCIALIZING RYALTRIS™ SEASONAL ALLERGIC RHINITIS NASAL SPRAY IN US

BRIEF-Hikma Pharmaceutical Enters Into Agreement To Commercialise Ryaltris™

* CO AND GLENMARK SPECIALTY S.A., UNIT OF GLENMARK PHARMACEUTICALS, ANNOUNCE SIGNING OF US LICENSE AGREEMENT TO COMMERCIALISE RYALTRIS

BRIEF-Glenmark Pharma Approves Raising Of Funds Upto $400 Million

* APPROVED THE RAISING OF FUNDS UPTO $400 MILLION Source text for Eikon: [http://bit.ly/2tW1qob] Further company coverage:

BRIEF-India's Glenmark Pharmaceuticals Dec Qtr Consol Profit From Cont Ops Rises

* DEC QUARTER CONSOL PROFIT FROM CONTINUING OPERATIONS 1.91 BILLION RUPEES VERSUS PROFIT OF 1.16 BILLION RUPEES YEAR AGO

BRIEF-Glenmark Pharmaceuticals To Consider Fund Raising Proposals

* TO CONSIDER PROPOSALS FOR RAISING OF FUNDS Source text for Eikon: Further company coverage:

BUZZ-India's Glenmark Pharma falls on CCI penalty

** Shares of Glenmark Pharmaceuticals Ltd fall as much as 2.4 percent to 551.50 rupees, their lowest since June 8

BUZZ-India's Glenmark Pharmaceuticals drops most in over 3 months

** Shares of Glenmark Pharmaceuticals Ltd fall nearly 5 pct to 505.5 rupees, their lowest since May 22

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up